Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $34.95, for a total transaction of $6,990,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $56,376,551.85. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00.
• On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00.

Roivant Sciences Trading Down 2.9%

ROIV stock opened at $32.87 on Thursday. The firm has a 50-day moving average of $32.48 and a two-hundred day moving average of $28.93. Roivant Sciences Ltd. has a 12 month low of $10.90 and a 12 month high of $37.00. The company has a market cap of $23.64 billion, a price-to-earnings ratio of -54.78 and a beta of 1.11.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Citigroup boosted their price objective on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. TD Cowen raised their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Institutional Trading of Roivant Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in shares of Roivant Sciences by 15.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after acquiring an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after acquiring an additional 34,341 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares during the period. Finally, M&T Bank Corp increased its holdings in Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after purchasing an additional 1,181 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.